

**Gloucester Healthcare Partnership Limited**  
**Financial Statements**  

---

**31 December 2018**



# **Gloucester Healthcare Partnership Limited**

## **Financial Statements**

**Year ended 31 December 2018**

<b>Contents</b>	<b>Page</b>
Directors' Report	1
Directors' Responsibilities Statement	3
Independent Auditors' Report to the Members of Gloucester Healthcare Partnership Limited	4
Profit and Loss Account and Statement of Comprehensive Income	7
Balance Sheet	8
Statement of Changes in Equity	9
Notes to the Financial Statements	10

# Gloucester Healthcare Partnership Limited

## Directors' Report

### Year ended 31 December 2018

The directors present their report and the audited financial statements of the company for the year ended 31 December 2018.

#### Principal activities and business review

The principal activity of the company is the provision of operational and maintenance services for the Gloucestershire Royal Hospital, in accordance with a Project Agreement entered into with Gloucestershire Hospitals National Health Service Trust.

The hospital became fully operational in 2004. The company is currently running the operational and maintenance services for the period to 22 February 2034, providing a full range of facilities management services under a contractual agreement that provides a regular income stream which is subject to deductions for service shortfalls and the unavailability of the facility.

The United Kingdom is due to leave the European Union by 31 October 2019. The terms on which the United Kingdom may withdraw from the European Union are not clear, and it is difficult to evaluate all of the potential implications on the company's trade, customers, suppliers and the wider economy. However, the company is not affected by the continued uncertainty surrounding the United Kingdom's membership of the European Union, as the cash flows generated from the PFI concession asset are secured under contract with Gloucestershire Hospitals National Health Service Trust, a government body.

The result for the company for the year is shown in the Profit and Loss Account and Statement of Comprehensive Income on page 7.

#### Directors

The directors who served the company during the year and up to the date of this report are shown below:

A Naafs

I Tayler

N Rae

R Little

F Schramm

(Resigned 17 January 2019)

#### Dividends

The directors approved and paid dividends of £545,000 (2017: £213,000) during the year.

#### Future developments

The updated forecast for the project confirms that it is performing satisfactorily and management of the scheme both logistically and financially remains under control. The directors remain confident that the company will maintain the current level of performance and keep meeting the obligations under the contract.

#### Donations

The company made no political donations during the year (2017: £nil).

#### Small company exemption

This report has been prepared in accordance with the special provisions relating to small companies within Part 15 of the Companies Act 2006. The directors have taken advantage of the small companies exemptions provided by Sections 415A and 415B of the Companies Act 2006, which includes those in relation to the exemption from certain requirements of the Directors' report and the available exemption to not prepare a Strategic report.

# Gloucester Healthcare Partnership Limited

## Directors' Report *(continued)*

Year ended 31 December 2018

### Disclosure of information to the auditors

In the case of each director in office at the date the Directors' Report is approved:

- so far as the director is aware, there is no relevant audit information of which the company's auditors are unaware; and
- they have taken all the steps that they ought to have taken as a director in order to make themselves aware of any relevant audit information and to establish that the company's auditors are aware of that information.

### Independent auditors


Pursuant to Section 487 of the Companies Act 2006, the auditors will be deemed to be reappointed and PricewaterhouseCoopers LLP will therefore continue in office.

---

### Going concern

The directors have reviewed the company's projected cash flows by reference to a financial model covering accounting periods up to 31 December 2034. The directors have also examined the current status of the company's principal contracts and likely developments in the foreseeable future. Having reviewed the available information, the directors consider that the company will be able to meet its financial obligations on the due dates for the foreseeable future. Accordingly, the directors consider that it is appropriate for the financial statements of the company to be prepared on a going concern basis.

This report was approved by the Board of directors on 20 June 2019 and signed on behalf of the Board by:



A. Naafs  
Director

Registered office:  
Part First Floor  
1 Grenfell Road  
Maidenhead  
Berkshire  
SL6 1HN

# Gloucester Healthcare Partnership Limited

## Directors' Responsibilities Statement

Year ended 31 December 2018

The directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulation.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have prepared the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards, comprising FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing the financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- state whether applicable United Kingdom Accounting Standards, comprising FRS 102, have been followed, subject to any material departures disclosed and explained in the financial statements;
- make judgements and accounting estimates that are reasonable and prudent; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006.

Signed on behalf of the Board by:



A Naafs  
Director

Registered office:  
Part First Floor  
1 Grenfell Road  
Maidenhead  
Berkshire  
SL6 1HN

Date:

28 June 2019

# **Gloucester Healthcare Partnership Limited**

## **Independent Auditors' Report to the Members of Gloucester Healthcare Partnership Limited**

**Year ended 31 December 2018**

### **Report on the audit of the financial statements**

#### **Opinion**

In our opinion, Gloucester Healthcare Partnership Limited's financial statements:

- give a true and fair view of the state of the company's affairs as at 31 December 2018 and of its profit for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards, comprising FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", and applicable law); and
- have been prepared in accordance with the requirements of the Companies Act 2006.

We have audited the financial statements, included within the Financial Statements (the "Annual Report"), which comprise: the Balance Sheet as at 31 December 2018; the Profit and Loss Account and Statement of Comprehensive Income and the Statement of Changes in Equity for the year then ended; and the notes to the financial statements, which include a description of the significant accounting policies.

#### **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) ("ISAs (UK)") and applicable law. Our responsibilities under ISAs (UK) are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### *Independence*

We remained independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, which includes the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

#### **Conclusions relating to going concern**

ISAs (UK) require us to report to you when:

- the directors' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the directors have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

We have nothing to report in respect of the above matters.

However, because not all future events or conditions can be predicted, this statement is not a guarantee as to the company's ability to continue as a going concern. For example, the terms on which the United Kingdom may withdraw from the European Union are not clear, and it is difficult to evaluate all of the potential implications on the company's trade, customers, suppliers and the wider economy.

# **Gloucester Healthcare Partnership Limited**

## **Independent Auditors' Report to the Members of Gloucester Healthcare Partnership Limited (continued)**

**Year ended 31 December 2018**

### **Reporting on other information**

The other information comprises all of the information in the Annual Report other than the financial statements and our auditors' report thereon. The directors are responsible for the other information. Our opinion on the financial statements does not cover the other information and, accordingly, we do not express an audit opinion or, except to the extent otherwise explicitly stated in this report, any form of assurance thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If we identify an apparent material inconsistency or material misstatement, we are required to perform procedures to conclude whether there is a material misstatement of the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report based on these responsibilities.

With respect to the Directors' Report, we also considered whether the disclosures required by the UK Companies Act 2006 have been included.

Based on the responsibilities described above and our work undertaken in the course of the audit, ISAs (UK) require us also to report certain opinions and matters as described below.

### *Directors' Report*

In our opinion, based on the work undertaken in the course of the audit, the information given in the Directors' Report for the year ended 31 December 2018 is consistent with the financial statements and has been prepared in accordance with applicable legal requirements.

In light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we did not identify any material misstatements in the Directors' Report.

### **Responsibilities for the financial statements and the audit**

#### *Responsibilities of the directors for the financial statements*

As explained more fully in the Directors' Responsibilities Statement set out on page 3, the directors are responsible for the preparation of the financial statements in accordance with the applicable framework and for being satisfied that they give a true and fair view. The directors are also responsible for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

#### *Auditors' responsibilities for the audit of the financial statements*

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

# **Gloucester Healthcare Partnership Limited**

## **Independent Auditors' Report to the Members of Gloucester Healthcare Partnership Limited (continued)**

**Year ended 31 December 2018**

### **Responsibilities for the financial statements and the audit (continued)**

#### *Auditors' responsibilities for the audit of the financial statements (continued)*

A further description of our responsibilities for the audit of the financial statements is located on the FRC's website at: [www.frc.org.uk/auditorsresponsibilities](http://www.frc.org.uk/auditorsresponsibilities). This description forms part of our auditors' report.

#### *Use of this report*

This report, including the opinions, has been prepared for and only for the company's members as a body in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and for no other purpose. We do not, in giving these opinions, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing.

### **Other required reporting**

#### **Companies Act 2006 exception reporting**

Under the Companies Act 2006 we are required to report to you if, in our opinion:

- we have not received all the information and explanations we require for our audit; or
- adequate accounting records have not been kept by the company, or returns adequate for our audit have not been received from branches not visited by us; or
- certain disclosures of directors' remuneration specified by law are not made; or
- the financial statements are not in agreement with the accounting records and returns.

We have no exceptions to report arising from this responsibility.

#### **Entitlement to exemptions**

Under the Companies Act 2006 we are required to report to you if, in our opinion, the directors were not entitled to: take advantage of the small companies exemption in preparing the Directors' Report; and take advantage of the small companies exemption from preparing a strategic report. We have no exceptions to report arising from this responsibility.

*Jonathan Studholme*

Jonathan Studholme (Senior Statutory Auditor)  
for and on behalf of PricewaterhouseCoopers LLP  
Chartered Accountants and Statutory Auditors  
Manchester

28 June 2019

# Gloucester Healthcare Partnership Limited

## Profit and Loss Account and Statement of Comprehensive Income

Year ended 31 December 2018

	Note	2018 £000	2017 £000
<b>Turnover</b>	<b>4</b>	<b>3,582</b>	<b>2,944</b>
Cost of sales		(2,465)	(2,037)
Administrative expenses		(180)	(165)
<b>Operating profit</b>		<b>937</b>	<b>742</b>
Interest receivable and similar income	7	1,864	1,935
Interest payable and similar expenses	8	(1,598)	(1,632)
<b>Profit before taxation</b>		<b>1,203</b>	<b>1,045</b>
Tax on profit	9	(267)	(287)
<b>Profit for the financial year</b>		<b>936</b>	<b>758</b>
Fair value movements on cash flow hedging instruments		1,225	899
Tax recognised in relation to change in fair value cash flow hedges	9	(208)	(153)
<b>Other comprehensive income for the year</b>		<b>1,017</b>	<b>746</b>
<b>Total comprehensive income for the financial year</b>		<b>1,953</b>	<b>1,504</b>

The notes on pages 10 to 19 form part of these financial statements.

All the activities of the company are from continuing operations.

# Gloucester Healthcare Partnership Limited

## Balance Sheet

As at 31 December 2018

		2018	2017
	Note	£000	Restated £000
<b>Current assets</b>			
Debtors: amounts falling due within one year	11	1,603	1,544
Debtors: amounts falling due after more than one year	11	29,604	30,133
Cash at bank and in hand		4,990	4,701
<b>Total current assets</b>		<b>36,197</b>	<b>36,378</b>
<b>Creditors: amounts falling due within one year</b>	12	<b>(1,763)</b>	<b>(1,675)</b>
<b>Net current assets</b>		<b>34,434</b>	<b>34,703</b>
<b>Total assets less current liabilities</b>		<b>34,434</b>	<b>34,703</b>
<b>Creditors: amounts falling due after more than one year</b>	13	<b>(31,234)</b>	<b>(33,177)</b>
<b>Provision for other liabilities</b>	16	<b>(2,980)</b>	<b>(2,714)</b>
<b>Net assets/(liabilities)</b>		<b>220</b>	<b>(1,188)</b>
<b>Capital and reserves</b>			
Called up share capital	17	38	38
Cash flow hedge reserve	18	(6,194)	(7,211)
Profit and loss account		6,376	5,985
<b>Total equity</b>		<b>220</b>	<b>(1,188)</b>

The notes on pages 10 to 19 form part of these financial statements.

The financial statements on pages 7 to 19 were approved by the Board of directors on ...  
and signed on behalf of the Board by:

*28 June 2019*

  
A. Naafs  
Director

Company registration number: 04341298

# Gloucester Healthcare Partnership Limited

## Statement of Changes in Equity

Year ended 31 December 2018

	Note	Called up share capital £000	Cash flow hedge reserve £000	Profit and loss account £000	Total equity £000
<b>At 1 January 2017</b>		38	(7,957)	5,440	(2,479)
Profit for the financial year		–	–	758	758
Other comprehensive income for the year:					
Fair value movements on cash flow hedging instruments		–	899	–	899
Tax recognised in relation to change in fair value cash flow hedges	9	–	(153)	–	(153)
<b>Total comprehensive income for the financial year</b>		–	746	758	1,504
Dividends paid and payable	10	–	–	(213)	(213)
<b>Total investments by and distributions to owners</b>		–	–	(213)	(213)
<b>At 31 December 2017</b>		38	(7,211)	5,985	(1,188)
Profit for the financial year		–	–	936	936
Other comprehensive income for the year:					
Fair value movements on cash flow hedging instruments		–	1,225	–	1,225
Tax recognised in relation to change in fair value cash flow hedges	9	–	(208)	–	(208)
<b>Total comprehensive income for the financial year</b>		–	1,017	936	1,953
Dividends paid and payable	10	–	–	(545)	(545)
<b>Total investments by and distributions to owners</b>		–	–	(545)	(545)
<b>At 31 December 2018</b>		<b>38</b>	<b>(6,194)</b>	<b>6,376</b>	<b>220</b>

The notes on pages 10 to 19 form part of these financial statements.

# **Gloucester Healthcare Partnership Limited**

## **Notes to the Financial Statements**

**Year ended 31 December 2018**

### **1. General information**

The company is a private company limited by shares incorporated in the United Kingdom, which is registered and domiciled in the United Kingdom at Part First Floor, 1 Grenfell Road, Maidenhead, Berkshire, SL6 1HN. The principal activity of the company is the provision of operational and maintenance services for the Gloucestershire Royal Hospital.

### **2. Statement of compliance**

These financial statements were prepared in accordance with Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland ("FRS 102") and the Companies Act 2006. The presentation currency of these financial statements is sterling.

The company's parent undertaking, Healthcare Providers (Gloucester) Limited, includes the company in its consolidated financial statements. The consolidated financial statements of Healthcare Providers (Gloucester) Limited are prepared in accordance with FRS 102 and are available to the public and may be obtained from Companies House, Crown Way, Cardiff, CF14 3UZ.

The accounting policies set out below have, unless otherwise stated, been applied consistently to all periods presented in these financial statements.

A number of balance sheet reclassifications have been performed in relation to the year ended 31 December 2017. Please see note 21 for further information.

### **3. Summary of significant accounting policies**

#### **Measurement convention**

The financial statements were prepared under the historical cost convention except that the following assets and liabilities are stated at their fair value: derivative financial instruments.

#### **Going concern**

The directors have reviewed the cash flow forecast and taking into account reasonable possible changes in operations, believe that the company will be able to settle liabilities as they fall due for payment for the foreseeable future and therefore consider that it is appropriate to prepare these financial statements on a going concern basis.

#### **Exemptions for qualifying entities under FRS 102**

The company is considered to be a qualifying entity (for the purposes of this FRS) and has applied the exemptions available under FRS 102 in respect of the following disclosures:

- Cash Flow Statement and related notes.
- Basic Financial Instruments and Other Financial Instrument Issues.

# Gloucester Healthcare Partnership Limited

## Notes to the Financial Statements *(continued)*

Year ended 31 December 2018

### 3. Summary of significant accounting policies *(continued)*

#### Critical accounting estimates and judgements

The preparation of financial statements in conformity with FRS 102 requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, income and expenses. The estimates and associated assumptions are based upon historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making judgements about carrying values of assets and liabilities that are not readily available from other sources. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an on-going basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period or in the period of revision and future periods if the revision affects both current and future periods. Certain critical accounting estimates in applying the company's accounting policies are described below:

Accounting for the service concession contract and finance debtor requires an estimation of service margins, finance debtor interest rates and associated amortisation profile which is based on forecasted results of the PFI contract. Quarterly management accounts are produced, which compare actual performance with a detailed financial model. Variances are investigated and consideration given to the impact of any major variances. The financial model is updated on a six monthly basis, to reflect actual performance to date and accommodate any changes in economic assumptions such as, RPI and the UK corporation tax rate. These processes ensure that the project remains robust and viable throughout the life of the contract.

#### Turnover

Turnover represents the value of services rendered, excluding sales related taxes, and is recognised to the extent that the company obtains the right to consideration in exchange for its performance. During the construction phase, which completed on 8 October 2004, revenues in excess of net operating and finance costs were deferred until completion of construction, are being released to the Profit and Loss Account over the remaining life of the concession. During the operational phase, turnover is recognised as contract activity progresses at a mark up on costs related to the provision of services. In line with FRS 102 23.22(a), the mark up is calculated based upon the forecast service revenues and costs over the concession period.

A lease premium income of £1,000,000 received from Gentian (GHP) Limited in December 2003, in respect of retail premises at the Gloucestershire Royal Hospital, is being released over the period of the lease, until February 2034, and in accordance with the underlease agreement of retail premises at the Gloucestershire Royal Hospital, the company receives an annual rental income from Gentian (GHP) Limited, for occupying a retail space within the hospital premises.

#### Taxation

Tax on the profit or loss for the year comprises current and deferred tax. Tax is recognised in the Profit and Loss Account except to the extent that it relates to items recognised directly in equity or other comprehensive income, in which case it is recognised directly in equity or other comprehensive income.

Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the balance sheet date, and any adjustment to tax payable in respect of previous years.

Deferred tax is provided on timing differences which arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in the financial statements. Deferred tax is not recognised on permanent differences arising because certain types of income or expense are non-taxable or are disallowable for tax or because certain tax charges or allowances are greater or smaller than the corresponding income or expense.

# Gloucester Healthcare Partnership Limited

## Notes to the Financial Statements *(continued)*

Year ended 31 December 2018

### 3. Summary of significant accounting policies *(continued)*

#### **Taxation *(continued)***

Deferred tax is recognised on trading losses carried forward and on the fair value movement of the swap derivative.

Deferred tax is measured at the tax rate that is expected to apply to the reversal of the related difference, using tax rates enacted or substantively enacted at the balance sheet date. Deferred tax balances are not discounted.

Deferred tax assets are recognised only to the extent that the directors consider that it is more likely than not that there will be suitable taxable profits from which the future reversal of the underlying timing differences can be deducted.

#### **Financial instruments**

##### *Trade and other debtors / creditors*

Trade and other debtors are recognised initially at transaction price less attributable transaction costs. Trade and other creditors are recognised initially at transaction price plus attributable transaction costs. Subsequent to initial recognition they are measured at amortised cost using the effective interest rate method, less any impairment losses in the case of trade debtors.

##### *Interest-bearing borrowings classified as basic financial instruments*

Interest-bearing borrowings are recognised initially at the present value of future payments discounted at a market rate of interest. Subsequent to initial recognition, interest-bearing borrowings are stated at amortised cost using the effective interest rate method, less any impairment losses.

##### *Cash and cash equivalents*

Cash and cash equivalents comprise cash balances and treasury deposits.

##### *Restricted cash balance*

The company is obligated to keep a separate cash reserve in respect of future major maintenance costs. This restricted cash balance, which is shown on the balance sheet within the "cash at bank and in hand" balance, amounts to £4,130,000 at the year end (2017: £4,136,000).

#### **Other financial instruments**

##### *Financial instruments not considered to be basic financial instruments (other financial instruments)*

Other financial instruments not meeting the definition of Basic Financial Instruments are recognised initially at fair value. Subsequent to initial recognition other financial instruments are measured at fair value with changes recognised in profit or loss except as follows:

- hedging instruments in a designated hedging relationship shall be recognised as set out below.

# Gloucester Healthcare Partnership Limited

## Notes to the Financial Statements *(continued)*

Year ended 31 December 2018

### 3. Summary of significant accounting policies *(continued)*

#### Derivative financial instruments and hedging

Derivative financial instruments are recognised at fair value. The gain or loss on remeasurement to fair value is recognised immediately in profit or loss. However, where derivatives qualify for hedge accounting, recognition of any resultant gain or loss depends on the nature of the item being hedged (see below).

#### *Cash flow hedges*

The company has entered into an interest rate swap and designated these as hedges for highly probable forecast transaction. The effective part of any gain or loss on the derivative financial instrument is recognised directly in other comprehensive income. Any ineffective portion of the hedge is recognised immediately in profit or loss. When a hedging instrument expires or is sold, terminated or exercised, or the entity discontinues designation of the hedge relationship but the hedged forecast transaction is still expected to occur, the cumulative gain or loss at that point remains in equity and is recognised in accordance with the above policy when the transaction occurs. If the hedged transaction is no longer expected to take place, the cumulative unrealised gain or loss recognised in equity is recognised in the Profit and Loss Account immediately.

#### Finance debtor

The company is an operator of a PFI contract. The underlying asset is not deemed to be an asset of the company under FRS 102 section 34.12C, because the risks and rewards of ownership as set out in that Standard are deemed to lie principally with the Authority.

During the construction phase of the project, all attributable expenditure was included in amounts recoverable on contracts and turnover. Upon becoming operational, the costs were transferred to the finance debtor. During the operational phase, income is allocated between interest receivable and the finance debtor using an asset specific interest rate. The remainder of the PFI unitary charge income is included within turnover in accordance with FRS 102 section 23.22(a). The company recognises income in respect of the services provided as it fulfils its contractual obligations in respect of those services and in line with the fair value of the consideration receivable in respect of those services.

#### Expenses

#### *Interest receivable and Interest payable*

Interest payable and similar expenses include interest payable on borrowings and associated on-going financing fees. Interest payable is recognised in the Profit and Loss Account, using the effective interest rate method.

Interest receivable and similar income include interest receivable on funds invested and interest recognised on the finance debtor based upon the finance debtor accounting policy above.

# Gloucester Healthcare Partnership Limited

## Notes to the Financial Statements *(continued)*

Year ended 31 December 2018

### 4. Turnover

Turnover arises from:

	2018 £000	2017 £000
Service income	3,440	2,806
Rental income	142	138
	<u>3,582</u>	<u>2,944</u>

The whole of the turnover is attributable to the principal activity of the company wholly undertaken in the United Kingdom.

### 5. Auditors' remuneration

	2018 £000	2017 £000
Audit of these financial statements	<u>9</u>	<u>9</u>

In addition, the company has borne the audit fee of £2,000 (2017: £2,000) of its immediate parent undertaking.

The company incurred tax fees of £3,000 (2017: £3,000) during the year.

### 6. Staff costs and directors' remuneration

The company had no employees during the year (2017: nil). No key management personnel received any remuneration during the year (2017: nil). The directors have no contract of service with the company. During the year the company incurred charges of £80,000 (2017: £77,000) from BBGI Management HoldCo S.a.r.l. (an indirect and wholly owned subsidiary of BBGI SICAV S.A., which are both registered and domiciled at 6, Route de Treves, Building E, L-2633 Senningerberg, Luxembourg) and £80,000 (2017: £77,000) from Semperian PPP Investment Partners No.2 Limited (which is registered and domiciled in the United Kingdom at 4th Floor, 1 Gresham Street, London, EC2V 7BX), for making available the services of the directors.

### 7. Interest receivable and similar income

	2018 £000	2017 £000
Bank interest receivable	22	5
Finance debtor interest receivable	1,842	1,930
	<u>1,864</u>	<u>1,935</u>

Interest is imputed on the finance debtor using an asset specific interest rate of 7%.

# Gloucester Healthcare Partnership Limited

## Notes to the Financial Statements *(continued)*

Year ended 31 December 2018

### 8. Interest payable and similar expenses

	2018 £000	2017 £000
Interest payable on bank loan	1,431	1,471
Interest payable on subordinated debt	164	158
Other interest payable and similar expenses	3	3
	<u>1,598</u>	<u>1,632</u>

### 9. Tax on profit

#### Tax expense

	2018 £000	2017 £000
<b>Deferred tax:</b>		
Origination and reversal of timing differences	267	287
<b>Tax on profit</b>	<u>267</u>	<u>287</u>

#### Tax recognised as other comprehensive income or equity

The aggregate deferred tax relating to items recognised as other comprehensive income or equity for the year was £(208,000) (2017: £(153,000)). The effect of changes in tax rates and laws is £24,000 (2017: £18,000).

#### Reconciliation of tax expense

The tax assessed on the profit before taxation for the year is higher than (2017: higher than) the standard rate of corporation tax in the UK of 19% (2017: 19.25%).

	2018 £000	2017 £000
Profit before taxation	1,203	1,045
Profit by rate of tax	229	201
Adjustment to tax charge in respect of prior periods	–	54
Effect of expenses not deductible for tax purposes	70	64
Adjust closing deferred tax to current rate of 19% (2017: 19.25%)	(351)	(359)
Adjust opening deferred tax to current rate of 19% (2017: 19.25%)	319	321
Effective interest rate adjustment	–	6
<b>Tax on profit</b>	<u>267</u>	<u>287</u>

#### Factors that may affect future tax expense

The UK corporation tax rate will reduce to 17% from 1 April 2020. This change was substantively enacted as part of the Finance Bill on 6 September 2016. This change has been reflected in the financial statements and will reduce the company's future current tax charge accordingly.

# Gloucester Healthcare Partnership Limited

## Notes to the Financial Statements *(continued)*

Year ended 31 December 2018

### 10. Dividends

Dividends paid during the year (excluding those for which a liability existed at the end of the prior year):

	2018 £000	2017 £000
Dividends on ordinary shares	545	213

During the year the company made a dividend payment of £545,000 (2017: £213,000) to its immediate parent undertaking, Healthcare Providers (Gloucester) Limited, which is registered and domiciled in the United Kingdom at Part First Floor, 1 Grenfell Road, Maidenhead, Berkshire, SL6 1HN.

### 11. Debtors

Debtors falling due within one year are as follows:

	2018 £000	2017 £000
Trade debtors	571	582
Finance debtor	1,009	940
Prepayments and accrued income	23	22
	<u>1,603</u>	<u>1,544</u>

Debtors falling due after one year are as follows:

	2018 £000	2017 £000
Deferred tax asset	1,269	1,477
Finance debtor	25,392	26,401
Prepayments and accrued income	2,943	2,255
	<u>29,604</u>	<u>30,133</u>

### 12. Creditors: amounts falling due within one year

	2018 £000	2017 Restated* £000
Bank loans and overdrafts	1,258	1,258
Trade creditors	110	107
Other taxation and social security	165	177
Subordinated debt (including accrued interest)	29	26
Accruals and deferred income	201	107
	<u>1,763</u>	<u>1,675</u>

\*Refer to note 21 for further information on the restated balances.

### 13. Creditors: amounts falling due after more than one year

	2018 £000	2017 Restated* £000
Bank loans and overdrafts	21,032	21,780
Subordinated debt	2,430	2,378
Swap liability	7,463	8,688
Accruals and deferred income	309	331
	<u>31,234</u>	<u>33,177</u>

\*Refer to note 21 for further information on the restated balances.

# Gloucester Healthcare Partnership Limited

## Notes to the Financial Statements *(continued)*

Year ended 31 December 2018

### 13. Creditors: amounts falling due after more than one year *(continued)*

Included within Bank loans and overdrafts is an amount repayable after five years of £17,748,000 (2017: £19,013,000) and included within subordinated debt are amounts repayable after five years of £2,430,000 (2017: £2,378,000).

Bank loan relates to senior secured funding granted by a consortium of banks led by Helaba (Landesbank Hessen-Thüringen Girozentrale). The senior loan facility is for a total value of £35,600,000.

The senior loan facility consists of a term loan facility of £34,500,000 which is repayable in fifty six, six-monthly instalments ending 21 August 2032. Bank loans and overdrafts of £21,032,000 (2017: £21,780,000) includes an outstanding loan facility of £21,250,000 (2017: £22,038,000) and an effective interest rate adjustment of £(218,000) (2017: £(258,000)) in relation to the senior loan facility. Interest is charged on amounts drawn under the facility at LIBOR + 0.75%.

The senior loan facility is secured by a fixed charge over all leasehold interests, book debts, project accounts and intellectual property of the company and by a floating charge over the company's undertakings and assets.

Subordinated debt of £2,430,000 (2017: £2,378,000) includes an unsecured loan facility of £2,382,000 (2017: £2,382,000) due to Healthcare Providers (Gloucester) Limited, and an effective interest rate adjustment of £48,000 (2017: £(4,000)) in relation to the subordinated loan facility. The subordinated loan facility bears interest at LIBOR + 4% and is fully repayable by 2034.

### 14. Deferred income

A lease premium of £1,000,000 from Gentian (GHP) Limited in respect of retail premises at the hospital is being released over the period of the lease, which expires in February 2034. At 31 December 2018, the balance outstanding is £331,000 (2017: £353,000).

### 15. Deferred tax

The deferred tax asset included in the balance sheet is as follows:

	2018 £000	2017 £000
Deferred tax on revaluation of fair value of derivatives	1,269	1,477

### 16. Provision for other liabilities

The deferred tax liability included in the balance sheet is as follows:

	2018 £000	2017 £000
Difference between accumulated amortisation and capital allowances	2,145	2,199
Losses carried forward	(365)	(608)
Short lease premium relief	1,169	1,086
FRS 102 transition - effective interest rate	31	37
	<u>2,980</u>	<u>2,714</u>

# Gloucester Healthcare Partnership Limited

## Notes to the Financial Statements *(continued)*

Year ended 31 December 2018

### 17. Called up share capital

Issued, called up and fully paid

	2018		2017	
	No.	£000	No.	£000
Ordinary shares of £1 each	37,884	38	37,884	38

### 18. Reserves

*Cash flow hedge reserve*

The hedge reserve comprises the effective portion of the cumulative net change in the fair value of cash flow hedging instruments related to hedged transactions that have not yet occurred.

### 19. Related parties

During the year the company entered into the following transactions with related parties:

	Transactions with related parties		Payables to related parties	
	2018	2017	2018	2017
	£000	£000	£000	£000
BBGI Management HoldCo S.a.r.l.	80	77	20	19
Healthcare Providers (Gloucester) Limited	164	158	2,459	2,404
Semperian PPP Investment Partners No.2 Limited	91	90	69	27
BBGI SICAV S.A.	11	13	18	8

The company incurred directors' fees of £80,000 (2017: £77,000) from Semperian PPP Investment Partners No.2 Limited (which is registered and domiciled in the United Kingdom at 4th floor, 1 Gresham Street, London, EC2V 7BX). At the year end there was £60,000 (2017: £19,000) payable to Semperian PPP Investment Partners No.2 Limited in respect of directors' fees.

The company incurred letter of credit fees of £11,000 (2017: £13,000) from Semperian PPP Investment Partners No.2 Limited (which is registered and domiciled in the United Kingdom at 4th floor, 1 Gresham Street, London, EC2V 7BX). At the year end there was £9,000 (2017: £8,000) payable to Semperian PPP Investment Partners No.2 Limited in respect of letter of credit fees.

The company incurred directors' fees of £80,000 (2017: £77,000) from BBGI Management HoldCo S.a.r.l. (an indirect and wholly owned subsidiary of BBGI SICAV S.A., which are both registered and domiciled at 6, Route de Treves, Building E, L-2633 Senningerberg, Luxembourg). At the year end there was £20,000 (2017: £19,000) payable to BBGI Management HoldCo S.a.r.l. in respect of directors' fees.

The company incurred letter of credit fees of £11,000 (2017: £13,000) from BBGI SICAV S.A. (the ultimate parent undertaking and controlling party, which is registered and domiciled at 6, Route de Treves, Building E, L-2633 Senningerberg, Luxembourg). At the year end there was £18,000 (2017: £8,000) payable to BBGI SICAV S.A. in respect of letter of credit fees.

The company incurred interest of £164,000 (2017: £158,000) on the subordinated loan facility payable to Healthcare Providers (Gloucester) Limited (which is registered and domiciled in the United Kingdom at Part First Floor, 1 Grenfell Road, Maidenhead, Berkshire, SL6 1HN). At the year end there was £2,459,000 (2017: £2,404,000) payable to Healthcare Providers (Gloucester) Limited in respect of the subordinated loan facility.

# Gloucester Healthcare Partnership Limited

## Notes to the Financial Statements *(continued)*

Year ended 31 December 2018

### 20. Parent undertaking

The company is a wholly owned subsidiary of Healthcare Providers (Gloucester) Limited ('the immediate parent undertaking'), which is registered and domiciled in the United Kingdom at Part First Floor, 1 Grenfell Road, Maidenhead, Berkshire, SL6 1HN.

At 31 December 2018, 50% of the share capital in the immediate parent undertaking was held by BBGI Investments S.C.A. (an indirect and wholly owned subsidiary of BBGI SICAV S.A., which are both registered and domiciled at 6, Route de Treves, Building E, L-2633 Senningerberg, Luxembourg), with the remaining 50% held by Semperian PPP Investment Partners No.2 Limited, which is registered and domiciled in the United Kingdom at 4th Floor, 1 Gresham Street, London, EC2V 7BX.

BBGI SICAV S.A. is listed on the London Stock Exchange, and is registered and domiciled at 6, Route de Treves, Building E, L-2633 Senningerberg, Luxembourg.

Semperian PPP Investment Partners No.2 Limited is a wholly owned subsidiary of Semperian PPP Investment Partners Holdings Limited, incorporated in Jersey.

There is no ultimate controlling party.

The largest group in which the results of the company are consolidated is that headed by Healthcare Providers (Gloucester) Limited, incorporated in the United Kingdom. Copies can be obtained from Companies House, Crown Way, Cardiff, CF14 3UZ.

### 21. Prior year adjustments

#### Reconciliation of equity as at 31 December 2017

	Original £000	Adjustment £000	Restated £000
<b>Current assets</b>			
Debtors: amounts due within one year	1,544	–	1,544
Debtors: amounts falling due after more than one year	30,133	–	30,133
Cash at bank and in hand	4,701	–	4,701
<b>Total current assets</b>	<b>36,378</b>	<b>–</b>	<b>36,378</b>
<b>Creditors: amounts due within one year</b>	<b>(1,186)</b>	<b>(489)</b>	<b>(1,675)</b>
<b>Net current assets</b>	<b>35,192</b>	<b>(489)</b>	<b>34,703</b>
<b>Creditors: amounts falling due after more than one year</b>	<b>(36,380)</b>	<b>489</b>	<b>(35,891)</b>
<b>Net assets</b>	<b>(1,188)</b>	<b>–</b>	<b>(1,188)</b>
<b>Capital and reserves</b>			
Called up share capital	38	–	38
Cash flow hedge reserve	(7,211)	–	(7,211)
Profit and loss account	5,985	–	5,985
<b>Total equity</b>	<b>(1,188)</b>	<b>–</b>	<b>(1,188)</b>

#### Notes to the reconciliation of equity

At 31 December 2017, an amount of £4,000 (2016: £55,000) in relation to the effective interest rate adjustment on the subordinated loan facility has been reclassified from payables due within one year to payables due after more than one year to correctly disclose the interest payable on the subordinated debt due within one year.

At 31 December 2017, an amount of £485,000 (2016: £498,000) in relation to interest payable on bank loans and overdrafts has been reclassified from payables due after more than one year to payables due within one year to correctly disclose the interest payable on bank loans and overdrafts due within one year.